Reporting and context from the 24X7 News newsroom.
Archive: CPR training aboard USS John Paul Jones, August 4, 2026. U.S. Navy / NAVCENT Public Affairs. Public domain. Resized and branded.The ALARM trial found earlier volunteer arrival with travel-time calculations or a wider geographic radius; it did not measure survival.
Archive: CPR training aboard USS John Paul Jones, August 4, 2026. U.S. Navy / NAVCENT Public Affairs. Public domain. Resized and branded.A preliminary trial in British Columbia and Columbus, Ohio, found similar bystander treatment rates with and without PulsePoint alerts.
Archive: Simvastatin packages in the United Kingdom, January 7, 2021. Whispyhistory / Wikimedia Commons, CC BY-SA 4.0. Resized and branded; derivative under the same license.STREAM studied older adults without existing cardiovascular disease; longer follow-up complicates a broad conclusion about stopping treatment.
Archive: Simvastatin packages in the United Kingdom, January 7, 2021. Whispyhistory / Wikimedia Commons, CC BY-SA 4.0. Resized and branded; derivative under the same license.Ez-PAVE compared starting a statin alone with starting a statin plus ezetimibe, while allowing treatment changes to reach LDL targets.
Archive: CDC blood-pressure screening, 2012. CDC / Yvonne Green, RN, CNM, MSN. Public domain; free source: CDC PHIL. No CDC or U.S. Government endorsement.OPTIMAL-DIABETES found a modest, statistically uncertain cardiovascular difference and more kidney-related events with intensive treatment.
Archive: CDC blood-pressure screening, 2012. CDC / Yvonne Green, RN, CNM, MSN. Public domain; free source: CDC PHIL. No CDC or U.S. Government endorsement.OPTIMAL-Stroke found fewer events with intensive treatment, alongside increased kidney-related adverse events.
Archive: CDC blood-pressure screening, 2012. CDC / Yvonne Green, RN, CNM, MSN. Public domain; free source: CDC PHIL. No CDC or U.S. Government endorsement.Preliminary REDUCE findings show better blood-pressure control; the trial did not test whether the drug prevents another stroke.
Archive: Cleveland Clinic’s Crile Building, September 23, 2015. Photo: HealthMonitor / Wikimedia Commons, CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/). Branding added; derivative under the same license.The Cleveland Clinic-led trial found similar major cardiovascular event rates with pelacarsen and placebo, despite lower lipoprotein(a) levels.
Archive: Brigham and Women’s Hospital, Boston, November 6, 2025. Ajay Suresh / CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Resized and branded.Newly presented findings show no significant reduction in heart attack, stroke or cardiovascular death in the high-risk trial population, despite lower inflammatory markers.
Company-reported findings extend a small adolescent heart-disease study beyond its placebo-controlled period.
Bill Cramer/Wonderful Machine, CC BY-SA 4.0; adapted by 24X7 NewsThe pharmaceutical distributor reported higher quarterly and annual revenue, set fiscal 2027 guidance and increased its dividend.
ajay_suresh / Wikimedia Commons / CC BY 2.0CVS intends to separate its pharmacy business from Aetna, Caremark and health services by mid-2028; shares closed sharply lower despite stronger earnings and raised guidance.
Vertex reported $3.44 billion in third-quarter revenue and lifted its full-year sales forecast to $13.15 billion to $13.25 billion.
The company said 255 patients enrolled in its Phase 2/3 study of CB03-154 in China; the announcement contains no treatment-outcome results.
Office of Senator Susan Collins / U.S. Senate. Official portrait; photographer and capture date not supplied. Crop and graphic by 24X7 News.The American Association of Kidney Patients announced its 2026 award, citing the Maine senator’s work on research and patient-centered policy.
Mark Vaughn / Florida State University; crop and graphic by 24X7 News.Florida State dedicated the new facility October 30 and named it for Wilton Simpson. The university says it will accommodate more than 150 researchers.
FDA / 24X7 News. Official background photograph of FDA headquarters; photographer and capture date not supplied. Cropped and branded by 24X7 News.The DNA-based immunotherapy is intended to reduce surgery frequency in adults with recurrent respiratory papillomatosis. Confirmatory research is still required.
The foundation says a portion of proceeds will support its work during a campaign ending November 13.
The nonprofit’s new commitment combines workforce training, cataract services and an AI-assisted screening partnership.
Tampa General Hospital, via its October 30 announcement. Supplied portrait; individual photographer and capture date not supplied. Graphic: 24X7 News.The hospital system announced a planned finance leadership transition, with Mark Runyon moving into special projects.
The provider says the Texas family-medicine clinic will offer weekday, evening and weekend hours.
The Ohio hospital announced the agreement October 30. The contract was signed October 28, and closing remains subject to regulatory and legal review.
Regeneron, company archival film (Vimeo 930750815), frame 00:14; capture date unknown. Natural crop and 24X7 News graphic.The company’s October 30 financial report separates rising collaboration income from its own product sales.
The medical-technology company said its quarterly performance fell short of management’s expectations.